Viatris' (VTRS) China business remains resilient despite concerns over the country's new volume-cont

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

Viatris’ second-quarter results were met with a negative market reaction, despite the company surpassing Wall Street’s revenue and non-GAAP profit expectations. Management attributed the quarter’s performance to strong commercial execution in Greater China, where investments in established brands and e-commerce channels drove double-digit growth. CEO Scott Smith emphasized that demand for cardiovascular products and the company’s strategic focus on higher-margin generics in North America contrib

According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30 million in cash at closing, funded via cash on hand, with up to $70 million in contingent […]

Greater China surges 16% as management raises full-year guidance.

Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year’s revenue to be around $14.75 billion, close to analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15% above analysts’ consensus estimates.

In early August 2026, Viatris Inc. reported higher second-quarter and year-to-date revenues, a six-month return to net profitability, raised its 2026 earnings guidance midpoint to US$14.75 billion, completed a US$1.15 billion share repurchase program covering 8.7% of shares, and affirmed a US$0.12 quarterly dividend. An interesting angle is that Viatris paired improved earnings and guidance with both capital returns and the FDA approval of its low-estrogen Gwyn Lo contraceptive patch,...

Viatris stock has delivered a strong 76.1% return over the past year, and the broader valuation checks still indicate the shares may be pricing in less than the company’s fundamentals could justify. Viatris is up 76.1% over the last 12 months, which puts more focus on whether the recent share price better reflects the company’s long term earnings power. Recent product news, including the FDA approval of the Gwyn Lo contraceptive patch and the agreement to transfer rights to TYRVAYA nasal...

Viatris raises 2026 guidance alongside completed buyback and fresh product approval Viatris (VTRS) has given investors a busy early August, pairing raised 2026 revenue guidance and completion of a multi year share repurchase program with new product news and an affirmed quarterly dividend. See our latest analysis for Viatris. The recent guidance lift, completion of a US$1.15b buyback and fresh product approval come after a strong run for Viatris, with a year to date share price return of...

The latest research on Viatris centers on a revised price target of US$22 per share and what that figure implies for investors following the story. Analysts are split, with more optimistic views pointing to execution on the product pipeline and cautious views questioning how fully the current stock price already reflects those expectations. As the article continues, you will see how this updated target fits into the evolving narrative around Viatris and how you can track the key signposts...

Viatris Inc (VTRS) delivers 3.5% operational revenue growth and raises full-year 2026 guidance, while navigating supply disruptions and competitive pressures.